Thrombospondins: Old players, new games

Current Opinion in Lipidology

Volumn 24, Issue 5, 2013, Pages 401-409

  Stenina Adognravi, Olga ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; CELL SURFACE RECEPTOR; GLUCOSE; THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THROMBOSPONDIN 3; THROMBOSPONDIN 4; THROMBOSPONDIN 5; UNCLASSIFIED DRUG;

AGING; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR SYSTEM; CELL INTERACTION; CELL SURFACE; CELLULAR IMMUNITY; DIABETES MELLITUS; EXTRACELLULAR MATRIX; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HEART MUSCLE; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOXIA; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE MIGRATION; MOLECULAR PATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

AGING; ANIMALS; ANOXIA; ATHEROSCLEROSIS; CARDIOMYOPATHIES; DIABETIC ANGIOPATHIES; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; PROTEIN STRUCTURE, TERTIARY; THROMBOSPONDINS;

EID: 84883777340     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283642912     Document Type: Review

References (98)

1. Lynch JM, Maillet M, Vanhoutte D, et al. A thrombospondin-dependent pathway for a protective ER stress response. Cell 2012; 149:1257-1268
2. Bornstein P, Agah A, Kyriakides TR. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol 2004; 36:1115-1125
3. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003; 22:63-71
4. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 2002; 161:831-839
5. Stenina OI, Topol EJ, Plow EF. Thrombospondins, their polymorphisms, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27:1886-1894
6. Bentley AA, Adams JC. The evolution of thrombospondins and their ligandbinding activities. Mol Biol Evol 2010; 27:2187-2197
7. Kyriakides TR, Bornstein P. Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 2003; 90:986-992
8. Bornstein P, Armstrong LC, Hankenson KD, et al. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol 2000; 19:557-568
9. Schellings MW, van Almen GC, Sage EH, Heymans S. Thrombospondins in the heart: Potential functions in cardiac remodeling. J Cell Commun Signal 2009; 3:201-213
10. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6:1-12
11. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A 1999; 96:14888-14893
12. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008; 65:700-712
13. Lawler J, Detmar M. Tumor progression: The effects of thrombospondin-1 and-2. Int J Biochem Cell Biol 2004; 36:1038-1045
14. Bonnefoy A, Daenens K, Feys HB, et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)-endothelial VWF from cleavage by ADAMTS13. Blood 2006; 107:955-964
15. Narizhneva NV, Razorenova OV, Podrez EA, et al. Thrombospondin-1 upregulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J 2005; 19:1158-1160
16. Bonnefoy A, Moura R, Hoylaerts MF. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 2008; 65:713-727
17. Frolova EG, Pluskota E, Krukovets I, et al. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res 2010; 107:1313-1325
18. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104:2641-2644
19. Corsetti JP, Ryan D, Moss AJ, et al. Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thromb Haemost 2011; 106:1170-1178
20. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923
21. Kato TYA, Murase Y, Hirashiki A, et al. Specific gene polymorphisms could be risk factors for coronary artery disease in individuals with or without hypertention. Circulation (Suppl) 2003; 108:IV712
22. Wessel J, Topol EJ, Ji M, et al. Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J 2004; 147:905-909
23. Cui J, Randell E, Renouf J, et al. Gender dependent association of thrombospondin-4 A387P polymorphism with myocardial infarction. Arterioscler Thromb Vasc Biol 2004; 24:e183-e184
24. Cui J, Randell E, Renouf J, et al. Thrombospondin-4 1186G>C (A387P) is a sex-dependent risk factor for myocardial infarction: A large replication study with increased sample size from the same population. Am Heart J 2006; 152:543; e1-5
25. Ashokkumar M, Anbarasan C, Saibabu R, et al. An association study of thrombospondin 1 and 2 SNPs with coronary artery disease and myocardial infarction among South Indians. Thromb Res 2011; 128:e49-e53
26. Stenina OI, Byzova TV, Adams JC, et al. Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 2004; 36:1013-1030
27. Tan FL, Moravec CS, Li J, et al. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A 2002; 99:11387-11392
28. Frolova EG, Sopko N, Blech L, et al. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J 2012; 26:2363-2373
29. Adolph KW. Relative abundance of thrombospondin 2 and thrombospondin 3 mRNAs in human tissues. Biochem Biophys Res Commun 1999; 258:792-796
30. Mustonen E, Aro J, Puhakka J, et al. Thrombospondin-4 expression is rapidly upregulated by cardiac overload. Biochem Biophys Res Commun 2008; 373:186-191
31. Zhao XM, Hu Y, Miller GG, et al. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. Circulation 2001; 103:525-531
32. Sezaki S, Hirohata S, Iwabu A, et al. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood) 2005; 230:621-630
33. Lawler J, Duquette M, Whittaker CA, et al. Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J Cell Biol 1993; 120:1059-1067
34. Wang D, Oparil S, Feng JA, et al. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 2003; 42:88-95
35. van Almen GC, Swinnen M, Carai P, et al. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 2011; 51:318-328
36. Fang C, Carlson CS, Leslie MP, et al. Molecular cloning, sequencing, and tissue and developmental expression of mouse cartilage oligomeric matrix protein (COMP). J Orthop Res 2000; 18:593-603
37. Cingolani OH, Kirk JA, Seo K, et al. Thrombospondin-4 is required for stretchmediated contractility augmentation in cardiac muscle. Circ Res 2011; 109:1410-1414
38. Reinecke H, Robey TE, Mignone JL, et al. Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc Pathol 2013; 22:91-95
39. Vanhoutte D, van Almen GC, Van Aelst LN, et al. Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. Eur Heart J 2013. [Epub ahead of print]
40. Belmadani S, Bernal J, Wei CC, et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol 2007; 171: 777-789
41. Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005; 111:2935-2942
42. Chatila K, Ren G, Xia Y, et al. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc Hematol Agents Med Chem 2007; 5:21-27
43. Schroen B, Heymans S, Sharma U, et al. Thrombospondin-2 is essential for myocardial matrix integrity: Increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004; 95:515-522
44. Cai H, Yuan Z, Fei Q, Zhao J. Investigation of thrombospondin-1 and transforming growth factor-beta expression in the heart of aging mice. Exp Ther Med 2012; 3:433-436
45. Pallero MA, Elzie CA, Chen J, et al. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 2008; 22:3968-3979
46. Rysa J, Leskinen H, Ilves M, Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 2005; 45:927-933
47. Mustonen E, Leskinen H, Aro J, et al. Metoprolol treatment lowers thrombospondin-4 expression in rats with myocardial infarction and left ventricular hypertrophy. Basic Clin Pharmacol Toxicol 2010; 107:709-717
48. Pohjolainen V, Mustonen E, Taskinen P, et al. Increased thrombospondin-2 in human fibrosclerotic and stenotic aortic valves. Atherosclerosis 2012; 220:66-71
49. Adams JC, Monk R, Taylor AL, et al. Characterisation of Drosophila thrombospondin defines an early origin of pentameric thrombospondins. J Mol Biol 2003; 328:479-494
50. Moura R, Tjwa M, Vandervoort P, et al. Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE-/-mice. Circ Res 2008; 103:1181-1189
51. Pluskota E, Stenina OI, Krukovets I, et al. Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. Blood 2005; 106:3970-3978
52. Stenina OI, Ustinov V, Krukovets I, et al. Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. FASEB J 2005; 19:1893-1895
53. Kvansakul M, Adams JC, Hohenester E. Structure of a thrombospondin C-Terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J 2004; 23:1223-1233
54. Floquet N, Dedieu S, Martiny L, et al. Human thrombospondin's (TSP-1) C-Terminal domain opens to interact with the CD-47 receptor: A molecular modeling study. Arch Biochem Biophys 2008; 478:103-109
55. Saumet A, Slimane MB, Lanotte M, et al. Type 3 repeat/C-Terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/ alphavbeta3 in promyelocytic leukemia NB4 cells. Blood 2005; 106:658-667
56. Miller TW, Isenberg JS, Shih HB, et al. Amyloid-beta inhibits No-cGMP signaling in a CD36-And CD47-dependent manner. PLoS One 2010; 5:e15686
57. Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol 2010; 159:1542-1547
58. Bauer EM, Qin Y, Miller TW, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 2010; 88:471-481
59. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: Implications for antiangiogenic therapies. Nat Rev Cancer 2009; 9:182-194
60. Isenberg JS, Qin Y, Maxhimer JB, et al. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 2009; 28:110-119
61. Isenberg JS, Romeo MJ, Maxhimer JB, et al. Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: Implications for human disease. Ann Surg 2008; 247:860-868
62. Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007; 109:1945-1952
63. Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007; 100:712-720
64. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 2006; 71:785-793
65. Isenberg JS, Ridnour LA, Dimitry J, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006; 281:26069-26080
66. Roberts DD, Miller TW, Rogers NM, et al. The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47. Matrix Biol 2012; 31:162-169
67. Zaslavsky A, Chen C, Grillo J, et al. Regional control of tumor growth. Mol Cancer Res 2010; 8:1198-1206
68. Almog N, Henke V, Flores L, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006; 20:947-949
69. Sanghamitra Bhattacharyya KS, Krukovets Irene, Nestor Carla, et al. Novel tissue-specific mechanism of regulation of angiogenesis and cancer growth in response to hyperglycemia. J Am Heart Assoc 2012; 1:e005967
70. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138:707-717
71. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosisdependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41-48
72. Tolsma SS, Volpert OV, Good DJ, et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity. J Cell Biol 1993; 122:497-511
73. Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010; 285:38923-38932
74. Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 2000; 157:1353-1363
75. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 2006; 339:633-641
76. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998; 93:1159-1170
77. Daniel C, Wiede J, Krutzsch HC, et al. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 2004; 65:459-468
78. Bhattacharyya S, Marinic TE, Krukovets I, et al. Cell type-specific posttranscriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J Biol Chem 2008; 283:5699-5707
79. Stenina OI, Krukovets I, Wang K, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation 2003; 107:3209-3215
80. Carron JA, Hiscott P, Hagan S, et al. Cultured human retinal pigment epithelial cells differentially express thrombospondin-1,-2,-3, and-4. Int J Biochem Cell Biol 2000; 32:1137-1142
81. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun 2000; 267:257-261
82. Wang S, Wu Z, Sorenson CM, et al. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 2003; 228:630-642
83. Li Y, Tong X, Rumala C, et al. Thrombospondin1 deficiency reduces obesityassociated inflammation and improves insulin sensitivity in a diet-induced obese mouse model. PLoS One 2011; 6:e26656
84. Rogers NM, Roberts DD, Isenberg JS. Age-Associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg 2012; 258:184-191. [Epub ahead of print]
85. Swinnen M, Vanhoutte D, Van Almen GC, et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 2009; 120:1585-1597
86. Starr ME, Hu Y, Stromberg AJ, et al. Gene expression profile of mouse white adipose tissue during inflammatory stress: Age-dependent upregulation of major procoagulant factors. Aging Cell 2013; 12:194-206
87. Frazier EP, Isenberg JS, Shiva S, et al. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol 2011; 30:154-161
88. Golledge J, Clancy P, Hankey GJ, Norman PE. Relation between serum thrombospondin-2 and cardiovascular mortality in older men screened for abdominal aortic aneurysm. Am J Cardiol 2013; 111:1800-1804
89. Miller TW, Kaur S, Ivins-O'Keefe K, Roberts DD. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol 2013. [Epub ahead of print]
90. Kaur S, Kuznetsova SA, Pendrak ML, et al. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem 2011; 286:14991-15002
91. Papageorgiou AP, Swinnen M, Vanhoutte D, et al. Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res 2012; 94:115-124
92. Grimbert P, Bouguermouh S, Baba N, et al. Thrombospondin/CD47 interaction: A pathway to generate regulatory T cells from human CD4- CD25-T cells in response to inflammation. J Immunol 2006; 177:3534-3541
93. Yabkowitz R, Dixit VM, Guo N, et al. Activated T-cell adhesion to thrombospondin is mediated by the alpha 4 beta 1 (VLA-4) and alpha 5 beta 1 (VLA-5) integrins. J Immunol 1993; 151:149-158
94. Rebres RA, Kajihara K, Brown EJ. Novel CD47-dependent intercellular adhesion modulates cell migration. J Cell Physiol 2005; 205:182-193
95. Vallejo AN, Mugge LO, Klimiuk PA, et al. Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells. J Immunol 2000; 164:2947-2954
96. Mateo V, Brown EJ, Biron G, et al. Mechanisms of CD47-induced caspaseindependent cell death in normal and leukemic cells: Link between phosphatidylserine exposure and cytoskeleton organization. Blood 2002; 100:2882-2890
97. Martin-Manso G, Navarathna DH, Galli S, et al. Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis. PLoS One 2012; 7:e48775
98. Soto-Pantoja DR, Miller TW, Pendrak ML, et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 2012; 8:1628-1642